Inceptor Bio executed an in-licensing agreement with the University of California, Santa Barbara for an investigational chimeric antigen receptor macrophage (CAR-M) therapy targeting difficult-to-treat tumors.
Macrophage cells naturally engulf viruses and bacteria through phagocytosis; when combined with a CAR construct to form a CAR-M, they can selectively target and engulf cancer cells and generate an immune response via modulation of the tumor microenvironment. Inceptor’s CAR-M technology plans to optimize the effectiveness of this therapeutic approach.
The technology was licensed from Denise Montell’s research lab at UCSB.
